Pharmaceutical company Alkem Laboratories Limited disclosed a 27.7% decrease in its consolidated net profit for the fourth quarter of fiscal 2026, mainly due to a one-time loss incurred during the period. The company’s net profit for the quarter ending March 2026 stood at Rs 236 crore, down from Rs 306 crore in the same quarter of the previous financial year. Alkem Labs attributed this decline to a one-time loss of Rs 135 crore recorded in the quarter.
Despite the profit dip, Alkem Labs experienced a robust growth in revenue, with consolidated revenue from operations climbing 14.6% year-on-year to Rs 3,603 crore in the March quarter, compared to Rs 3,144 crore reported in the corresponding period of the previous financial year. The company’s EBITDA surged by 32.2% to Rs 517 crore from Rs 391 crore in the year-ago quarter. The EBITDA margin also saw an improvement, rising to 14.4% from 12.4% in the same quarter of FY25.
Alkem Laboratories also declared a final dividend of Rs 10 per equity share for fiscal 2026, estimating a total payout of nearly Rs 119.57 crore to shareholders. The company set August 7 as the record date for determining shareholders eligible for the final dividend. The dividend payment is contingent upon shareholders’ approval at the upcoming annual general meeting and is scheduled to be disbursed from September 1 onwards.
Earlier in February 2026, Alkem Labs had announced an interim dividend of Rs 43 per share. In the preceding financial years, the company had paid dividends of Rs 8 per share in August 2025, Rs 37 per share in February 2025, and Rs 5 per share in August 2024. Additionally, the company appointed Madhurima Singh as Executive Director for a five-year term, effective from December 20.
